

febuxostat (ULORIC)

Diagnosis Considered for Coverage:

- Chronic treatment of hyperuricemia in patients with gout - who have an inadequate response to maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable
- Prevention of hyperuricemia in patients receiving chemotherapy

Coverage Criteria:

For chronic hyperuricemia in patients with gout:

- Inadequate response, intolerable side effect, or contraindication to allopurinol, **and**
- Dose does not exceed 80 mg per day.

For prevention of hyperuricemia in patients receiving chemotherapy:

- Dose does not exceed 120 mg per day for up to 9 days (or 60 mg per day for up to 14 days) per chemo cycle.

Coverage Duration: one year

Effective Date: 09/27/2023